Addition of a PHD inhibitor to established clinical expansion protocols for human adoptive cell therapy (ACT) using tumour-infiltrating lymphocytes (TILs) or chimeric antigen receptor (CAR)-transduced T cells is a feasible and potentially effective therapeutic strategy to improve the functional quality of tumour-specific T cells [308]. The gene discussed is PDC; the disease is neoplasm.